M.E.L. van der Burg

3.5k total citations
69 papers, 2.4k citations indexed

About

M.E.L. van der Burg is a scholar working on Reproductive Medicine, Oncology and Surgery. According to data from OpenAlex, M.E.L. van der Burg has authored 69 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Reproductive Medicine, 29 papers in Oncology and 23 papers in Surgery. Recurrent topics in M.E.L. van der Burg's work include Ovarian cancer diagnosis and treatment (32 papers), Cancer Treatment and Pharmacology (14 papers) and Endometrial and Cervical Cancer Treatments (13 papers). M.E.L. van der Burg is often cited by papers focused on Ovarian cancer diagnosis and treatment (32 papers), Cancer Treatment and Pharmacology (14 papers) and Endometrial and Cervical Cancer Treatments (13 papers). M.E.L. van der Burg collaborates with scholars based in Netherlands, Belgium and Italy. M.E.L. van der Burg's co-authors include Jaap Verweij, G. Stoter, Ronald de Wit, Martin J. van den Bent, A.T. van Oosterom, Hans C. van Houwelingen, J.P. Neijt, M. van Lent, Wim L.J. van Putten and A.C.M. van Lindert and has published in prestigious journals such as The Lancet, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

M.E.L. van der Burg

68 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M.E.L. van der Burg Netherlands 27 961 910 664 452 417 69 2.4k
J. B. Vermorken Netherlands 27 1.5k 1.5× 922 1.0× 918 1.4× 611 1.4× 736 1.8× 96 3.0k
Kenneth Webster United States 30 769 0.8× 1.2k 1.4× 845 1.3× 452 1.0× 481 1.2× 76 3.1k
J. J. Kavanagh United States 32 879 0.9× 1.2k 1.4× 754 1.1× 859 1.9× 360 0.9× 95 3.0k
Seiji Isonishi Japan 21 799 0.8× 969 1.1× 454 0.7× 798 1.8× 227 0.5× 80 2.2k
Alexander Kennedy United States 34 947 1.0× 1.3k 1.5× 795 1.2× 684 1.5× 451 1.1× 99 3.5k
Jean Hurteau United States 29 1.1k 1.2× 1.3k 1.4× 657 1.0× 1.1k 2.5× 328 0.8× 90 3.2k
Carmela Pisano Italy 26 706 0.7× 862 0.9× 321 0.5× 532 1.2× 261 0.6× 95 1.9k
Susana M. Campos United States 28 1.6k 1.7× 899 1.0× 319 0.5× 859 1.9× 449 1.1× 101 3.3k
Paul R. Kucera United States 17 1.1k 1.1× 2.3k 2.5× 1.4k 2.0× 573 1.3× 225 0.5× 32 3.3k
Agustin A. García United States 31 1.5k 1.6× 836 0.9× 339 0.5× 1.1k 2.4× 681 1.6× 114 3.1k

Countries citing papers authored by M.E.L. van der Burg

Since Specialization
Citations

This map shows the geographic impact of M.E.L. van der Burg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.E.L. van der Burg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.E.L. van der Burg more than expected).

Fields of papers citing papers by M.E.L. van der Burg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.E.L. van der Burg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.E.L. van der Burg. The network helps show where M.E.L. van der Burg may publish in the future.

Co-authorship network of co-authors of M.E.L. van der Burg

This figure shows the co-authorship network connecting the top 25 collaborators of M.E.L. van der Burg. A scholar is included among the top collaborators of M.E.L. van der Burg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.E.L. van der Burg. M.E.L. van der Burg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Burg, M.E.L. van der, Ignace Vergote, Wendy Onstenk, et al.. (2012). Long-term results of weekly paclitaxel carboplatin induction therapy: An effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer. European Journal of Cancer. 49(6). 1254–1263. 23 indexed citations
3.
Vencken, P.M.L.H., Mieke Kriege, M.E.L. van der Burg, et al.. (2011). Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Annals of Oncology. 22(6). 1346–1352. 154 indexed citations
4.
Wijk, F.H. van, M.E.L. van der Burg, Curt W. Burger, Ignace Vergote, & Helena C. van Doorn. (2009). Management of Surgical Stage III and IV Endometrioid Endometrial Carcinoma. International Journal of Gynecological Cancer. 19(3). 431–446. 10 indexed citations
5.
6.
Helleman, Jozien, Maurice P.H.M. Jansen, Theo M. Luider, et al.. (2007). Serum proteomic patterns for ovarian cancer monitoring. International Journal of Gynecological Cancer. 18(5). 985–995. 19 indexed citations
7.
Jong, Diederick De, Sharon Lie Fong, Cornelis G. Gerestein, et al.. (2007). Preoperative Predictors for Residual Tumor after Surgery in Patients with Ovarian Carcinoma. Oncology. 72(5-6). 293–301. 26 indexed citations
8.
Burg, M.E.L. van der, et al.. (2006). Primary Surgery At University Hospitals Improves Survival Of Ovarian Cancer-A Prospective Nationwide Study In Finland. International Journal of Gynecological Cancer. 16. 621–621. 1 indexed citations
9.
Berns, E., Corneel Coens, Paul van Diest, et al.. (2006). Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865). European Journal of Cancer. 42(15). 2539–2548. 22 indexed citations
10.
Jongh, Felix E. de, Ruben N. van Veen, Ronald de Wit, et al.. (2003). Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. British Journal of Cancer. 88(8). 1199–1206. 214 indexed citations
11.
Polée, M., H.W. Tilanus, F. Eskens, et al.. (2003). Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus. Annals of Oncology. 14(8). 1253–1257. 14 indexed citations
12.
Polée, M., Wim C.J. Hop, T.C. Kok, et al.. (2003). Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. British Journal of Cancer. 89(11). 2045–2050. 81 indexed citations
13.
Burg, M.E.L. van der, S.C. Henzen‐Logmans, J.G.M. Klijn, et al.. (2001). Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. British Journal of Cancer. 85(9). 1359–1367. 75 indexed citations
14.
Gelderblom, Hans, Alex Sparreboom, Maja J.A. de Jonge, et al.. (2001). Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer. British Journal of Cancer. 85(8). 1124–1129. 11 indexed citations
15.
Sparreboom, Alex, Maja J.A. de Jonge, V van Beurden, et al.. (1997). Pharmacokinetics and oral bioavailability of 9-amino-camptothecin PEG1000 capsules. European Journal of Cancer. 33. S246–S246. 1 indexed citations
16.
Hilkens, P.H.E., M.E.L. van der Burg, J. Moll, et al.. (1995). Effect of an ACTH(4–9) analogue on cisplatin neuropathy of longstanding duration: a phase II study. Clinical Neurology and Neurosurgery. 97(2). 139–141. 3 indexed citations
17.
Hilkens, P.H.E., André Planting, M.E.L. van der Burg, et al.. (1994). Clinical course and risk factors of neurotoxicity following cisplatin in an intensive dosing schedule. European Journal of Neurology. 1(1). 45–50. 11 indexed citations
18.
Henzen‐Logmans, S.C., M.E.L. van der Burg, John A. Foekens, et al.. (1992). Occurrence of epidermal growth factor receptors in benign and malignant ovarian tumors and normal ovarian tissues: an immunohistochemical study. Journal of Cancer Research and Clinical Oncology. 118(4). 303–307. 16 indexed citations
19.
Oosterom, A.T. van, W.W. ten Bokkel Huinink, M.E.L. van der Burg, et al.. (1991). Phase II clinical trial of doxifluridine in patients with advanced ovarian cancer. European Journal of Cancer and Clinical Oncology. 27(6). 747–749. 9 indexed citations
20.
Burg, M.E.L. van der, Frits B. Lammes, & Jaap Verweij. (1990). The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Annals of Oncology. 1(4). 301–302. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. B. Vermorken Breakdown of academic impact, for papers by Kenneth Webster Breakdown of academic impact, for papers by J. J. Kavanagh Breakdown of academic impact, for papers by Seiji Isonishi Breakdown of academic impact, for papers by Alexander Kennedy Breakdown of academic impact, for papers by Jean Hurteau Breakdown of academic impact, for papers by Carmela Pisano Breakdown of academic impact, for papers by Susana M. Campos Breakdown of academic impact, for papers by Paul R. Kucera Breakdown of academic impact, for papers by Agustin A. García
Rankless by CCL
2026